By IDSE News Staff
The FDA approved a new antibiotic, imipenem-cilastatin-relebactam (IMI/REL; Recarbrio, Merck), to treat adults with complicated urinary tract infections (cUTI) and complicated intraabdominal infections (cIAI).
IMI/REL is a combination of imipenem/cilastatin and relebactam. Imipenem is a penem antibacterial drug, which is already approved; cilastatin sodium is a renal dehydropeptidase inhibitor; and relebactam is a novel beta-lactamase inhibitor. Cilastatin limits the renal